Outlook Therapeutics OTLK
NASDAQ OTLK
$0.69 +0.01 (+1.94%)
As of: Aug 21, 2026 · 11:57 AM EDT

Outlook Therapeutics (OTLK) Net Margin (2015 - 2025)

Outlook Therapeutics (OTLK) posted quarterly Net Margin of 14482.19% for Q3 2025, up 1181.77% quarter-over-quarter from 1338.75% in Q2 2025.

Outlook Therapeutics (OTLK) Net Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Net Margin for 6 consecutive years, with 14482.19% the latest figure, recorded in Q3 2025.

  • In Q3 2025, Net Margin changed N/A year-over-year to 14482.19%; the TTM figure through Sep 2025 stood at 795.13% (changed N/A YoY), while the FY2025 annual figure was 4416.22%, changed N/A from the prior year.
  • Net Margin advanced to 14482.19% in Q3 2025 per OTLK's latest filing, from 1338.75% in the prior quarter.
  • Across five years, Net Margin topped out at 14482.19% in Q3 2025 and bottomed at 1338.75% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Vertex Pharmaceuticals 139.78 Bn 131.92 Bn 2.84 Bn 32.99%
2 Regeneron Pharmaceuticals 86.56 Bn 78.57 Bn 3.93 Bn 30.23%
3 Argenx Se 65.48 Bn 60.29 Bn 1.37 Bn 31.16%
4 Moderna 59.12 Bn 53.98 Bn 52.00 Mn -539.31%
5 BeOne Medicines 42.10 Bn 37.00 Bn 1.53 Bn 13.90%
6 Alnylam Pharmaceuticals 31.75 Bn 28.45 Bn 992.69 Mn 12.74%
7 BioNTech SE 28.12 Bn 9.72 Bn 668.28 Mn -16.51%
8 Insmed 27.58 Bn 26.42 Bn 358.27 Mn -3.12%
9 Royalty Pharma 27.20 Bn 26.36 Bn - 12.09%
10 Outlook Therapeutics 94.27 Mn 83.03 Mn -8,265.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 14,482.19%
Jun 30, 2025 -1,338.75%
Sep 30, 2019 -175.25%
Jun 30, 2019 -787.71%
Mar 31, 2019 -1,760.92%
Dec 31, 2018 -926.60%
Sep 30, 2018 -1,638.80%
Jun 30, 2018 -1,176.92%
Mar 31, 2018 -1,108.74%
Dec 31, 2017 -2,296.48%
Sep 30, 2017 -260.16%
Jun 30, 2017 -1,758.72%
Mar 31, 2017 -2,654.21%
Dec 31, 2016 -6,300.21%
Sep 30, 2016 -2,135.40%
Jun 30, 2016 -6,101.20%
Mar 31, 2016 -459.63%
Dec 31, 2015 -1,789.51%
Sep 30, 2015 -3,692.45%
Jun 30, 2015 -960.06%